INTRODUCTION
Genome editing technologies based on the clustered regularly interspaced short palindromic repeats (CRISPR)-associated endonuclease Cas9 enable rapid and efficient modification of endogenous genes in a variety of cell types, allowing for analysis of gene function in many organs in vivo. CRISPR-Cas9 induces DNA double strand breaks (DSBs) at single-guide RNA (sgRNA)-specific loci in the genome, which are repaired through either non-homologous end-joining (NHEJ) or homology-directed repair (HDR) pathways. While NHEJ introduces unpredictable pattern of insertion or deletion (indel) mutations, HDR directs a precise recombination event between a homologous DNA donor template and the damaged DNA site (Cong et al., 2013; Cox et al., 2015; Doudna and Charpentier, 2014; Heidenreich and Zhang, 2016; Jinek et al., 2012; Mali et al., 2013; Sander and Joung, 2014; Wang et al., 2013; Yang et al., 2013) . Thus, HDR can be used to precisely introduce sequence insertions, deletions or mutations by encoding the desired changes in the donor template DNA.
While HDR-based genome editing has been demonstrated to be useful for precise genome editing, application of HDR-based genome editing has been limited to mitotically dividing cells. This is because HDR had previously been found to occur primarily in the S and G2 phases of the cell cycle in mitotically dividing cells. In fact, HDR was found to occur rarely in postmitotic cells such as neurons (Chapman et al., 2012; Cox et al., 2015; Panier and Durocher, 2013; Rothkamm et al., 2003) . Thus, in the brain, HDR-based genome editing has been performed previously only in dividing cells such as neuronal progenitors in the embryo. With this strategy, we and other groups succeeded in inserting a tag sequence into a gene of interest, enabling the monitoring of the endogenous protein encoded by the gene with the tag (Mikuni et al., 2016; Uemura et al., 2016) . On the other hand, tag insertion via NHEJ-based genome editing has been achieved in postmitotic cells (Auer et al., 2014; Maresca et al., 2013; Suzuki et al., 2016) . However, this method lacks the precision of HDR and is subject to indel mutations. Therefore, precise genome editing via HDR has been a challenge in postmitotic cells.
A number of methods have been used to deliver genome editing machinery in vivo. In the previous studies to induce HDR in the brain in vivo, in utero electroporation (IUE) has been used to deliver HDR machinery into neuronal progenitor cells (Mikuni et al., 2016; Uemura et al., 2016) . In addition, adeno-associated virus (AAV) has been used for gene delivery in a wide variety of tissues including the brain, because they can robustly infect both dividing and non-dividing cells with low immunogenicity and toxicity. It has been reported that AAV can serve as a donor template for homologous recombination at higher efficiencies than non-viral approaches, presumably due to the efficient nuclear delivery of the vector genome, the single-strand nature of the genome and the effect of inverted terminal repeats (ITRs) (Barzel et al., 2015; Gaj et al., 2016; Russell and Hirata, 1998) . Moreover, the combined use of endonuclease to induce DSBs with AAV has been reported to increase the frequency of AAV-mediated gene targeting by several orders of magnitudes via unknown mechanisms (Dever et al., 2016; Gaj et al., 2016; Porteus et al., 2003) . Thus, AAV-based HDR assisted by CRISPR-Cas9 may allow us to efficiently induce HDR, even in postmitotic cells such as neurons. In the present study, we show that it is possible to perform efficient HDR-mediated genome editing not only in mitotic cells but also in postmitotic neurons in the brain by delivering HDR template with AAV. By using either Cas9 knockin mice (Chiou et al., 2015; Platt et al., 2014) or Cas9-expressing AAV, we demonstrate that efficient HDR-mediated sequence insertion can be performed in postmitotic neurons as well as in mitotic neuronal progenitors and glial cells. Through this approach, virus-mediated single-cell labeling of endogenous proteins via HDR (vSLENDR), we achieved highly efficient tagging of endogenous proteins in primary dissociated and organotypic slice cultures in vitro and various brain areas and cell types in developing and adult brains in vivo. We further demonstrate that vSLENDR allows us to label endogenous proteins in mice models of age-related human neurological disorders at $1 year old. Thus, HDR-mediated genome editing can be performed in virtually any cell type, area, and age across the brain, widely expanding the applicability of genome engineering technologies in the broad field of neuroscience.
RESULTS

HDR-Mediated Genome Editing in the Embryonic Brain
HDR occurs more efficiently in dividing cells (Mikuni et al., 2016) . Thus, to develop AAV-mediated genome editing technique via HDR, we first targeted dividing neuronal progenitor cells in the embryo by intraventricular administration of AAV encoding HDR machinery. Intraventricular administration would allow widespread transgene expression throughout the brain due to the penetration of AAV into the brain parenchyma including the ventricular zone (Passini et al., 2003; Rahim et al., 2012) . To test this strategy, we aimed to insert the human influenza hemagglutinin (HA) tag or monomeric EGFP (mEGFP) sequence into b-Actin, which expresses ubiquitously in most of cell types, and into CaMKIIa, which expresses exclusively in neurons (Mikuni et al., 2016) .
HDR-mediated genome editing requires delivering three components in the same cells: sgRNA, donor template DNA, and Cas9. We designed single AAV vectors encoding the following two components: (1) a U6-sgRNA expression cassette targeting the vicinity of the start codon of b-Actin or CaMKIIa, and (2) an HDR template containing the HA tag or mEGFP sequence flanked by $1 kb sequences homologous to b-Actin or CaMKIIa, respectively (termed AAV-HDR hereafter) ( Figure 1A ). To minimize the potential effects of gene knockdown through NHEJ, we used previously validated sgRNA targeting sequences in which CRISPR-Cas9 cleavage sites were located in 5 0 -UTR of b-Actin and CaMKIIa (Mikuni et al., 2016) (Figures 1C and 1F) . We packaged the designed vectors with serotype 1 (AAV1), which was known to provide high transduction efficiency and tropism in both neurons and glia in vivo (Aschauer et al., 2013) . As for Cas9, we utilized H11 Cas9 mice (termed Cas9 mice hereafter), where Streptococcus pyogenes Cas9 (SpCas9) is constitutively expressed under control of the ubiquitous CAG promoter (Chiou et al., 2015) . To infect dividing neuronal progenitor cells, we injected AAV-HDR for either b-Actin or CaMKIIa into the lateral ventricle of Cas9 or wild-type mice brain at embryonic days (E) 10-16 ( Figure 1B) . We analyzed the HA signal by immunohistochemistry using anti-HA antibody, or directly imaged mEGFP fluorescence at postnatal days (P) 14-42 ( Figures 1D, 1E , 1G-1I, S1, S2, and S3A-S3C). We observed strong HA staining or mEGFP fluorescence in brain slices of Cas9 mice, suggesting that the tag sequences were successfully integrated into the genome. Only background-level fluorescence was observed in brain slices of wild-type mice ( Figures 1D, 1E , 1G, 1H, S2A, and S2B), indicating that the integration into the genome requires CRISPRCas9-mediated DSBs. HA-or mEGFP-b-Actin was observed in a number of NeuN-positive (neuronal) and -negative cells distributed in entire brain regions including the olfactory bulb, retina, cerebral cortex, hippocampus, striatum, thalamus, hypothalamus, cerebellum, midbrain, and spinal cord ( Figures 1I, S1 , and S2). In contrast, consistent with the neuron-and region-specific expression of CaMKIIa, HA-or mEGFP-CaMKIIa was found only in neurons, but not in glia, in specific brain areas, including the olfactory bulb, cerebral cortex, hippocampus, striatum, superior/inferior colliculus, and cerebellum where CaMKIIa is expressed ( Figures 1I, S1 , and S2). To test whether the HA tag or mEGFP sequence was precisely inserted as intended in the genome, we performed PCR amplification of the targeted loci using primers for the HA tag or mEGFP sequence and for the genomic sequence of b-Actin or CaMKIIa outside of the homology arm (''recombination primer set'' in Figures 1C, 1F, 1J-1Q ). The PCR fragments were amplified from the genomic DNAs extracted from the AAV-HDR-infected brains of Cas9 mice, but not from those of wild-type mice ( Figures 1J, 1L, 1N , and 1P). In contrast, when a primer set specific for the genomic sequence of b-Actin or CaMKIIa (''control primer set'' in Figures 1C, 1F , and 1J-1Q) was used, PCR fragments were amplified both in Cas9 mice and wild-type mice. Furthermore, DNA sequencing analysis of the amplified DNA fragments by the recombination primer set revealed that the HA tag or mEGFP sequence was precisely inserted at the N terminus of b-Actin or CaMKIIa as expected (Figures 1K, 1M, 1O, and 1Q) . Thus, in utero intraventricular delivery of single AAV-HDR into Cas9 mice allows for brain-wide, site-specific sequence insertion via CRISPR-Cas9-mediated HDR.
HDR-Mediated Genome Editing in Distinct Cell-Types in the Brain
Because most cell types in the brain are generated in temporally distinct phases, intraventricular delivery of viral vectors enables transgene expression in different cell types and areas in a cell birthdate-dependent manner (Sauvageot and Stiles, 2002) . Indeed, we observed neurons expressing HA (or mEGFP)-CaMKIIa (only pyramidal neurons) or HA (or mEGFP)-b-Actin (both pyramidal and PV-positive inhibitory neurons) in the cortex when virus was injected at E10-E13 ( Figures 1I, S1 , and S2). Furthermore, we observed HA-b-Actin in tyrosine hydroxylase (TH)-positive dopaminergic neurons in the ventral tegmental area (VTA) in the midbrain when injected at E10, while most of HA-b-Actin-positive cells in VTA were glial cells when injected at E16 (Figures 1I and S1F ). In the hippocampus, HA-positive neurons were predominantly CA1 pyramidal neurons and dentate gyrus (DG) granule cells when injected at E10, while we found that most of the HA-positive neurons were dentate granule cells but only a small fraction of them was CA1 pyramidal neurons when injected at E16 ( Figure S1H and Table S1 ). In the molecular layer of the cerebellum, we observed HA-positive, calbindin-positive Purkinje cells when injected at E10 but none when injected at E12 and E16. Instead, most of the HA-positive cells were Bergman glia and stellate cells at the later stage ( Figure S1I and Table S1 ). In retina, a large number of HA-positive ganglion cells and bipolar cells were observed when injected at E10, while no HA-positive cell was found when injected at E14 and E16 ( Figure S1J and Table S1 ). Thus, in utero intraventricular injection of AAV-HDR enables targeting of various cell types regulated by the timing of injection.
When AAV-HDR was injected into the lateral ventricle of P1 pups of Cas9 mice ( Figure S4 ), most of HA-b-Actin-positive cells in the hippocampus and cortex were astrocytes ( Figure S4B ), consistent with the peak of astrocyte proliferation during the perinatal period (Ge et al., 2012; Sauvageot and Stiles, 2002) . We also observed HA-b-Actin or HA-CaMKIIa-positive neurons in the olfactory bulb and DG in the hippocampus, where new neurons are continuously generated from dividing neuronal progenitors in the embryonic and adult brain (Figures S4B-S4E and S4G) (Gage, 2000) . Intriguingly, we also observed a small fraction of HA-b-Actin or HA-CaMKIIa positive cells among pyramidal neurons in the CA1 and CA3 of the hippocampus and in the cortex ( Figures S4B, S4C , and S4F). These results suggest that vSLENDR enables HDR-mediated genome editing in postmitotic neurons.
HDR-Mediated Genome Editing in Postmitotic Neurons
Based on the results showing the sequence insertion in postmitotic neurons by neonatal intraventricular AAV-HDR injection, albeit at low efficiency, we further examined whether vSLENDR can be used for HDR-mediated genome editing in postmitotic neurons using in vitro system. We prepared organotypic hippocampal slice cultures from Cas9 or wild-type mice at P5-P6. At day in vitro (DIV) 8, we applied AAV-HDR for HA-CaMKIIa together with AAV encoding EGFP (AAV-EGFP) as an infection marker directly onto cultures ( Figure 2A ). Seven days after AAV-HDR transduction, HA-CaMKIIa-positive neurons were observed in the entire hippocampal slice including CA1, CA3, and DG in Cas9 mice, while only background-level fluorescence was observed in wild-type mice ( Figure 2B ). HA-CaMKIIa signals were found mostly in excitatory neurons (pyramidal neurons in CA1 and CA3 and granule cells in DG), consistent with the expression profile of CaMKIIa. The number of HA-CaMKIIa-positive neurons reached at $30% among mEGFP-positive cells (CA1, HA/EGFP: 28.4% ± 3.5%, n = 497 cells/3 slices; HA/ NeuN: 17.1% ± 1.5%, n = 823 cells/3 slices) when we applied 5.4 3 10 9 GC (0.5 mL of AAV-HDR at a concentration of $1.1 3 10 13 GC/mL; 100% in Figures 2C and 2D ). The efficiency was decreased nonlinearly when we reduced the dose of AAV-HDR ( Figures 2C and 2D ). Similarly, when we used AAV-HDR for mEGFP-CaMKIIa or mEGFP-b-Actin, many mEGFPCaMKIIa or mEGFP-b-Actin-positive cells were observed in entire hippocampal slice cultures in Cas9 mice, while only background-level fluorescence was observed in wild-type mice (Figures 2E, 2F, . We again observed mEGFPtagged proteins in cell types that are known to express the target proteins: mEGFP-CaMKIIa fluorescence was observed exclusively in excitatory neurons, while mEGFP-b-Actin fluorescence was observed in both neurons and glia (Figures 2E and 2F) .
To further confirm the applicability of vSLENDR to genome editing in postmitotic cells for other genes/loci, we targeted a gene encoding a ubiquitous signaling protein ERK2. We designed and applied AAV-HDR to insert the HA sequence into the N terminus of ERK2 in organotypic hippocampal cultures from Cas9 mice ( Figure 2G ). A number of HA-ERK2-positive cells were observed both in neurons and glial cells in the entire hippocampal slice in Cas9 mice, while only background-level fluorescence was observed in wild-type mice ( Figure 2H ). The number of HA-ERK2-positive neurons was $15% among EGFP-positive cells (CA1, HA/EGFP: 14.3% ± 1.9%, n = 343 cells/3 slices; HA/ NeuN: 9.5% ± 1.7%, n = 532 cells/3 slices). Notably, HA-ERK2 signals were mainly found in the cytosol but accumulated into the nucleus with bicuculline treatment ( Figure 2H , left and middle), consistent with previous studies showing the activitydependent nuclear translocation of ERK2 (Zhai et al., 2013) . In addition, when we injected AAV-HDR for HA-ERK2 into the lateral ventricle of P1 pups of Cas9 mice, HA-ERK2-positive neurons and astrocytes were observed in the hippocampus and cortex ( Figure S4H ). While all experiments above have been performed with AAV1, AAV serotype 9 (AAV9) has been also widely used for infecting brain cells (Aschauer et al., 2013) . Thus, we prepared AAV-HDR using AAV9 for HA-CaMKIIa and compared its HDR efficiency with AAV1-based AAV-HDR. We found that the efficiency of AAV9-based AAV-HDR was comparable to that of AAV1-based AAV-HDR in neurons in organotypic cultured slices ( Figures 2I and 2J , AAV9, CA1, HA/EGFP: 29.7% ± 2.4%, n = 330 cells/3 slices; HA/NeuN: 16.0% ± 1.1%, n = 604 cells/ 3 slices). All the experiments hereafter have been performed using AAV1-based AAV-HDR.
While we designed all constructs so that the DSBs are made in the non-coding region to minimize the effects of on-target indel formation (Mikuni et al., 2016) , indel-mediated knockout may occur, especially in cells that did not undergo HDR. Thus, we estimated the frequency of indel-mediated knockout in the AAV-based system, by immunostaining using the specific antibody against endogenous CaMKIIa in organotypic hippocampal slice cultures infected with AAV-HDR for CaMKIIa ( Figure S5D ). We found that endogenous CaMKIIa was not deleted in 98.1% of infected neurons ( Figure S5E ), suggesting that our strategy rarely causes knockout of the target gene. We also confirmed that the targeted HA and mEGFP sequence are inserted in the genome as designed by PCR amplification of the targeted locus of CaMKIIa, b-Actin, or ERK2, followed by DNA sequencing analysis of the amplified DNA fragments (Figures 2K-2R ). Taken together, these results demonstrate that AAV-mediated HDR enables precise, targeted sequence insertion in postmitotic neurons in organotypic slice cultures and could be broadly applied to other genomic targets, although the efficiency could vary depending on the target gene.
Since the HDR efficiency in organotypic slices was a steep function of the dose of AAV-HDR, we next measured the dose dependency of the HDR efficiency in mitotic and postmitotic cells in dissociated hippocampal culture, where the concentration of AAV-HDR can be controlled more quantitatively. We prepared dissociated hippocampal cultures from Cas9 and wildtype mice at E17 and applied AAV-HDR for mEGFP-b-Actin or mEGFP-CaMKIIa together with AAV encoding mCherry (AAVmCherry) as infection marker into the culture media at DIV10 ( Figure 3A ). Four days after infection, cultures were fixed and subjected to immunocytochemistry using postmitotic neuronal marker NeuN antibody. When a high dose of AAV-HDR was used (2-4 3 10 10 GC/mL), mEGFP-b-Actin fluorescence was See also Figures S5A-S5E and Tables S2 and S3. than $2 3 10 9 GC/mL, mEGFP-b-Actin was observed also in neurons (NeuN positive). These results suggested that HDR in postmitotic neurons requires $100-fold higher concentration of AAV-HDR compared to that in mitotic cells in this system.
Dual AAV System for HDR-Mediated Genome Editing
To expand vSLENDR to animals other than Cas9 knockin mice, we next sought a system to deliver Cas9 with AAV in addition to AAV-HDR. Because AAV has a limited transgene capacity (up to $5 kb including ITRs) (Wu et al., 2010) , we employed a dual AAV system, one expressing Cas9 and the other expressing a guide RNA and the donor DNA (i.e., AAV-HDR). In order to package the large size of SpCas9 tagged with Myc ($4.2 kb) under the control of a ubiquitous promoter into AAV vectors, we utilized a short form of constitutively acting elongation factor 1a (EFS) promoter ($0.25 kb) and a minimal synthetic polyadenylation signal (48 bases) (AAV-EFS-Cas9 hereafter, $4.8 kb in total) ( Figure 4A ) (Gray et al., 2011; Kostic et al., 2003; Swiech et al., 2015) . We transduced AAV-EFS-Cas9 together with AAV encoding EGFP into hippocampal-dissociated cultures and confirmed nuclear expression of Cas9 in all infected cells by immunocytochemistry using anti-Myc tag antibody ( Figure 4B ). Next, we transduced AAV-EFS-Cas9 and AAV-HDR for HA-CaMKIIa together with AAV-EGFP into hippocampal dissociated neurons prepared from wild-type mice at DIV10 ( Figure 4C ). HA-CaMKIIa signal was observed in a population of NeuN-positive neurons ( Figure 4D ), indicating that the dual AAV system enables efficient HDR-mediated genome editing in both mitotic cells and postmitotic neurons in vitro.
Taking advantage of the flexibility of the dual AAV system, which can be used for animals other than mice, we next assessed the specificity of AAV-HDR-mediated genome editing using rats and mice. Because mouse and rat share sgRNA targeting sequences of CaMKIIa (100% match) ( Figure 4E, top) , AAV-HDR for mouse CaMKIIa can make DSBs at specific loci of rat CaMKIIa. However, because the mouse and rat genome has similar but not identical sequences to those of homology arm of AAV-HDR for CaMKIIa ($80%-90% similarity) (Figure 4E , bottom; Table S2 ), HDR should occur only in targeted animals. To test whether this is the case, we transduced AAV-HDR for mEGFP-CaMKIIa with AAV-EFS-Cas9 into organotypic slice cultures from wild-type mice or rats ( Figure 4F ). Consistent with our hypothesis, mEGFP signal was observed in mouse slice cultures, but not in rat slice cultures co-transduced with AAV-HDR for mEGFP-mouse CaMKIIa and AAV-EFS-Cas9 ( Figure 4G , top). In contrast, when we transduced AAV-HDR for mEGFPrat CaMKIIa and AAV-EFS-Cas9, mEGFP signal was observed in rat slice cultures, but not in mouse slice cultures ( Figure 4G , bottom). These results demonstrate that AAV-mediated HDR in postmitotic neurons occurs in a homology-sequence-dependent manner.
To confirm that the immunostained signal was specifically from the HA tag fused to the N terminus of CaMKIIa as intended, we utilized a conditional knockout mouse, in which exon 2 of CaMKIIa can be deleted by the expression of Cre recombinase (Hinds et al., 2003) . We prepared hippocampal organotypic slice cultures from wild-type or conditional CaMKIIa knockout mice and transduced AAV encoding Cre recombinase (AAV-Cre) together with AAV, which conditionally expressed tdTomato as a Cre reporter (AAV-FLEX-tdTomato) at DIV2. We then applied AAV-EFS-Cas9 and AAV-HDR for HA-CaMKIIa onto cultures at DIV8 and performed immunohistochemistry using anti-HA antibody at DIV15 (Figures 4H and S5F ). The strong HA signal was observed in a significant number of wild-type CA1 and DG neurons (CA1, HA/tdTomato: 6.2% ± 1.2%, n = 375 cells/3 slices), but not in tdTomato-positive, CaMKIIa-deleted neurons (CA1, n = 374 cells/3 slices) ( Figures 4I, 4J , S5G, and S5H). These results indicated that the observed HA signal was specifically from HA-CaMKIIa as intended.
HDR-Mediated Genome Editing in the Adult Brain In Vivo
Next, we asked whether vSLENDR can be applied to neurons in the adult brain in vivo. We first applied the single AAV system to the adult mice brain and stereotaxically injected AAV-HDR for HA-CaMKIIa or HA-b-Actin together with AAV-EGFP into the cerebral cortex or hippocampus of adult Cas9 mice at P48-P58 ( Figures 5A and S6A) . The mice were fixed around 3 weeks after injection and their brain sections were subjected to immunohistochemistry using anti-HA or NeuN antibodies. We observed strong HA-CaMKIIa staining in a large number of neurons, but not in glial cells, in the cerebral cortex and hippocampal DG and CA3 of Cas9 mice ( Figures 5B-5F We next applied the dual AAV system to various brain regions in vivo in 1-to 2-month-old wild-type mice ( Figures 5G and S6E) . We observed HA-CaMKIIa staining in neurons, but not in glia, in injected brain regions, i.e., the cerebral cortex, amygdala, and striatum ( Figures 5H-5M ). In the cerebral cortex, the knockin efficiency in the dual AAV system was similar to that achieved by the single AAV system in Cas9 mice (dual AAV system, HA/ EGFP: 12.8%, n = 344 cells; HA/NeuN: 5.2%, n = 854 cells) (Figures 5C and 5I) . No obvious HA signal was observed in a control experiment where we injected only AAV-HDR for HA- (Figures 5H-5M) . Moreover, the efficiency of mEGFP-CaMKIIa knockin was comparable to that of HA-CaMKIIa knockin in the striatum ( Figures S6F and S6G , mEGFP/mCherry: 12.2%, n = 368 cells), suggesting that HDR efficiency is relatively independent of the length of the insertion. Taken together, the data demonstrate that the single and dual AAV systems allow for precise sequence insertion with comparable efficiency in both mitotic cells and postmitotic neurons in the adult brain in vivo.
HDR-Mediated Genome Editing in Aged, Disease-Model Mice
Given that the dual AAV system can be used for the brain of adult animals other than Cas9 knockin mice, the dual AAV system would greatly accelerate experiments using the disease mouse models, particularly models of age-related human neurological disorders, by skipping the process of crossing the animals with Cas9 knockin mice. To demonstrate this, we applied the dual AAV system for mEGFP-b-Actin to a mouse model of Alzheimer's disease expressing a mutant form of the human amyloid protein precursor (J20 mice) (Mucke et al., 2000) . Because the dendritic spine pathology has been implicated in Alzheimer's disease, we aimed to image the structure and number of dendritic spines by the fluorescence of mEGFP fused to endogenous b-Actin ( Figure S2H ) (Mikuni et al., 2016) .
We injected AAV-EFS-Cas9, AAV-HDR for mEGFP-b-Actin, and AAV-mCherry into the hippocampus of J20 mice and their littermate controls at $1 year old (P354). Two weeks after injection, mice were fixed and subjected to immunohistochemistry using anti-NeuN antibody ( Figure 6A ). mEGFP-b-Actin fluorescence was observed in the injected side of the CA1 hippocampus in both J20 mice and littermate control ( Figures 6B and  6C) . The mEGFP-b-Actin fluorescence was highly accumulated in dendritic spines and thus served as a convenient marker for highlighting spines ( Figures 6D and 6E) . Consistent with previous studies, we found that spine number was significantly reduced in J20 mice ( Figure 6F ; p = 0.01, Student's t test) (Pozueta et al., 2013) . These results showed that the dual AAV system can be applied to brains of aged mice with various genetic backgrounds.
DISCUSSION
In this study, we have developed vSLENDR, which allows HDRmediated precise genome editing both in mitotic and postmitotic cells in the brain through the use of an AAV-mediated delivery system. Through this approach, we achieved highly efficient sequence insertion in primary dissociated and organotypic slice cultures in vitro and in various brain areas and cell types in developing and adult brains in vivo. Previously, precise genome editing has been primarily limited to dividing cells, due to low HDR activity in non-dividing cells (Chapman et al., 2012; Cox et al., 2015; Heidenreich and Zhang, 2016; Orthwein et al., 2015; Panier and Durocher, 2013; Rothkamm et al., 2003) . This poses a significant challenge especially for the in vivo application of HDR, since most adult tissue is composed of non-dividing cells. In the current study, we overcome this problem by using AAV to effectively deliver genome editing machinery in target cells.
The exact mechanism by which AAV enables highly efficient HDR remains elusive. AAV has been reported to allow gene targeting by conventional homologous recombination mechanisms (Deyle and Russell, 2009 ). Importantly, AAV-mediated gene targeting frequencies are much higher than conventional transfection or electroporation approaches, presumably due to the efficient nuclear delivery of vector genomes, the single-strand nature of the genome, and the effect of ITRs (Barzel et al., 2015; Gaj et al., 2016; Russell and Hirata, 1998) . Although the efficiency of AAV-mediated gene targeting by itself is too low for most of somatic tissue in vivo, especially for postmitotic cells, the induction of DSBs by endonuclease can increase the frequency of AAV-mediated gene targeting by several orders of magnitudes (Dever et al., 2016; Gaj et al., 2016; Porteus et al., 2003) . This increased recombination efficiency by AAV likely enabled efficient HDR-mediated genome editing in postmitotic neurons in the adult brain in our study. Since HDR in postmitotic neurons requires much higher concentration of AAV-HDR than what is required for mitotic cells, it appears that a large copy number of template DNA is necessary for the induction of HDR in postmitotic neurons. Indeed, we achieved efficient HDRmediated genome editing in dividing neuronal progenitors by intraventricular administration, and thereby perhaps lower concentration than that of local injection in the adult brain, of AAV-HDR. The unprecedentedly high HDR efficiency (up to $15%-30%) in postmitotic cells in vitro and in vivo for multiple genes (CaMKIIa, b-actin, and ERK2) strongly suggests the broad applicability of vSLENDR for many other genes/loci. However, it should be noted that the HDR efficiency could be different from target to target. Indeed, recent studies have shown that the HDR efficiency is affected by many factors such as sequences in and around the target, sgRNA design, the distance between the insertion site and DSBs, the size of the insert, the length of the homology arms, and the activity of the endogenous repair systems (Lin et al., 2014; Moreno-Mateos et al., 2015; Paquet et al., 2016; Xu et al., 2015) .
Because the efficiency of HDR is substantially lower than that of NHEJ in many systems, alternative strategies have been developed for targeted sequence insertion via NHEJ using engineered nucleases, where the exogenous DNA fragment is directly ligated at DSBs (Auer et al., 2014; Maresca et al., 2013; Suzuki et al., 2016) . In the current study, we achieved $15% in vivo knockin efficiency in the cerebral cortex both by the single AAV system in Cas9 mice and by the dual AAV system in wild-type mice. These numbers are comparable to the reported efficiency of sequence insertion in postmitotic neurons using the NHEJ-mediated strategy (Suzuki et al., 2016) . In addition, HDR-based genome editing is advantageous over NHEJbased techniques as it enables precise introduction of any desired changes, such as point mutations and deletions, incorporated in the template DNA at the specific genomic locus homologous to the template. Furthermore, HDR allows for simultaneous genome editing at two different target genomic loci (Mikuni et al., 2016) .
We show that the gene-editing efficiency achieved by the dual AAV system is comparable to that achieved by the single AAV system in the cerebral cortex in vivo (12.8% versus 14.8%, Figures 5C and 5I) . Analogously, the editing efficiency was similar between these delivery systems in organotypic hippocampal slice cultures in vitro (CA1, 7.6% versus 6.2%; Figures 2C and 4J ). On the other hand, in the embryonic brain, HDR occurred more efficiently in the single AAV system than in the dual AAV system ( Figure S3 ). Thus, our results indicate that the dual AAV system allows us to perform highly efficient HDRbased genome editing in postmitotic cells (but not in embryonic cells) as well as providing us with much higher flexibility. The flexibility of the dual AAV system has been highlighted by our results showing that efficient HDR-based genome-editing is possible in organotypic slices in rats ( Figure 4G ) and in a mouse model of Alzheimer's disease at $1 year old (Figure 6 ). Cas9 knockin rats have not been developed yet and it would take a long time to breed the disease model crossed with Cas9 knockin mice. In both cases, the dual AAV system would be the favorable solution.
We confirmed that HA or mEGFP sequences were precisely inserted as intended at the N terminus of b-Actin, CaMKIIa, or ERK2 by DNA sequencing following PCR amplification of the targeted locus. To minimize the effects of on-target indel formation, we designed all constructs so that the DSBs are made in the non-coding region. Previously, using the similar strategy, we showed that the target protein was not deleted in 98.7% of the transfected neurons and the expression level was not changed (Mikuni et al., 2016) . In this study, we showed that endogenous CaMKIIa was not deleted in 98.1% of the neurons infected with AAV-HDR for HA-CaMKIIa ( Figure S5E ). However, potential effects of NHEJ have to be carefully evaluated depending on the purpose of experiments.
Another potential caveat of vSLENDR is that CRISPR-Cas9 may potentially generate DSBs at unwanted off-target sites. However, sequence insertion is unlikely to occur at those sites since HDR is highly specific to the sequence of homology arms of the template DNA. Indeed, no HA-labeled cells were observed by immunohistochemistry when we knocked out the targeted gene. In addition, the subcellular localization pattern of tagged b-Actin, CaMKIIa, and ERK2 was always consistent with that reported previously. Furthermore, consistent with the endogenous gene regulation of b-Actin, CaMKIIa, and ERK2, tagged b-Actin or ERK2 was ubiquitously observed in both neurons and glia in the entire brain, while tagged CaMKIIa was specifically found in neurons in limited brain regions. The specificity of this technique could be further enhanced by using novel Cas9 variants with minimum or no offtarget effects while retaining comparable on-target cleavage activity (Kleinstiver et al., 2016; Slaymaker et al., 2016) .
We have demonstrated that vSLENDR is applicable to virtually any brain area, cell type, and age of interest. Recently, we and other groups reported techniques for site-specific sequence insertion for single-cell labeling of endogenous proteins via CRISPR-Cas9-mediated HDR by introducing HDR machinery to dividing neuronal progenitors in the embryonic brain with IUE (Mikuni et al., 2016; Uemura et al., 2016) . However, because IUE-based techniques can be applied to limited area and age of the embryonic brain, it is difficult to target deep or broad areas in the brain. When applied to the embryo, AAV-based HDR can edit the genome in widespread regions of the brain including deep brain structures. Thus, systematic analysis of protein localization may be possible by combining this approach with whole-brain clearing and imaging method (Chung et al., 2013; Hama et al., 2011; Ke et al., 2016; Susaki et al., 2014) . Precise genome editing in a specific brain region is possible by injecting AAV encoding HDR machinery to specific brain regions in adult in vivo. Therefore, the production of Cre-dependent AAV expressing Cas9 would enable cell-type-specific genome editing by combining with the hundreds of different Cre-driver lines (Gerfen et al., 2013; Taniguchi et al., 2011) . Furthermore, the dual AAV system described here might be directly adapted to other mammalian species, opening the possibility of precise genome engineering in a variety of organisms, including non-human primates, in which genetic tools are limited. Thus, virus-mediated precise genome editing in the brain will provide a versatile tool for both basic and translational neuroscience.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
STAR+METHODS Primary dissociated cultures
Hippocampal primary dissociated cultures were prepared according to the standard procedures. Briefly, hippocampi dissected from both male and female mice at E17 were treated with 0.25% trypsin (Lonza) and 0.05 mg/mL DNaseI (Roche Applied Science) in Hanks' Balanced Salt Solution (GIBCO) at 37 C for 20 min. The dissociated hippocampal neurons were plated on poly-L-lysine (Sigma Aldrich)-coated 12 mm glass coverslips in 24-well dish and maintained in neurobasal medium (GIBCO) supplemented with B-27 (GIBCO), GlutaMAX (GIBCO), and penicillin/streptomycin (GIBCO) at 37 C in a 5% CO 2 humidified atmosphere. The half of the culture medium was exchanged with fresh medium every week.
Organotypic slice cultures
Organotypic cortical slice cultures were prepared according to the standard procedures (Stoppini et al., 1991) . In brief, coronal hippocampal slices of 350 mm thickness were dissected from both male and female mice at P5-6 or rats at P7 using a McIlwain tissue chopper (Ted Pella) . The slices were plated on a plated on hydrophilic PTFE membranes (Millicell, Millipore) and maintained in culture medium containing MEM medium (GIBCO), 20% horse serum (GIBCO), 1 mM L-glutamine, 1 mM CaCl 2 , 2 mM MgSO 4 , 12.9 mM DGlucose, 5.2 mM NaHCO 3 , 30 mM HEPES, 0.075% Ascorbic acid, 1 mg/mL Insulin at 37 C in a 5% CO 2 humidified atmosphere. The culture medium was exchanged with fresh medium every other day.
METHOD DETAILS
DNA constructs
To generate AAV-HDR for HA or mEGFP-b-Actin/CaMKIIa/ERK2, we first constructed targeting vectors containing HDR donor template DNAs. The $2 kb homology sequence flanking the each side of the target site for b-Actin/CaMKIIa/ERK2 was synthesized and subcloned into the pUC57 vector (Genewiz). HA or mEGFP sequence was then inserted into the target site of the homology sequence of b-Actin/CaMKIIa/ERK2. The resulting HDR template DNA was cloned into the pAAV backbone from PX551 gifted from F. Zhang (Addgene Plasmid #60957) (Swiech et al., 2015) , yielding the HDR donor template for HA and/or mEGFP-b-Actin/CaMKIIa/ERK2 (Table S2 ). To incorporate the sgRNA expression cassette into the targeting vectors, pX330-b-Actin/CaMKIIa/ERK2 which contains human U6 promoter and sgRNA specific for b-Actin/CaMKIIa/ERK2 (sgRNA target sequence: b-Actin, tgtgtcttgatagttcgcca; CaMKIIa, ctgcctgcccagtgccagga, ERK2: cggcggctgtgcagccaaca) was used as a PCR template. The sgRNA expression cassettes were amplified with Phusion DNA polymerase (Thermo Scientific) and cloned into the targeting vectors for HA-and/or mEGFPb-Actin/CaMKIIa/ERK2, yielding AAV-HDR for HA-b-Actin/CaMKIIa/ERK2 and mEGFP-b-Actin/CaMKIIa. To generate an AAV vector to express the human codon-optimized SpCas9 under the control of a ubiquitous promoter, we utilized the EFS promoter and synthetic polyadenylation signal (Gray et al., 2011; Kostic et al., 2003; Swiech et al., 2015) . lentiCRISPR v2 construct was a gift from F. Zhang (Addgene Plasmid #52961) (Sanjana et al., 2014) and used as a PCR template for EFS promoter. Myc tag was added by PCR to the N terminus of SpCas9 using pX551 as a template. PCR amplified Myc-SpCas9 fragment was then joined with EFS promoter by overlap extension PCR. The resulting EFS-Myc-SpCas9 was cloned into the pAAV backbone from pX551, yielding AAV-EFS-Cas9. All obtained constructs were sequenced and verified.
Genomic PCR and DNA sequencing To isolate genomic DNA from the AAV-transduced brains or organotypic slices, DNeasy Blood and Tissue Kit (QIAGEN) was used according to the manufacturer's instruction. Using the extracted DNA as a template, we performed genomic PCR using the following primers: HA-F, 5 0 -cccatacgatgttccagatt-3 0 ; HA-R, 5 0 -gcgtaatctggaacatcgtatg-3 0 ; GFP-F, 5 0 -catggtcctgctggagttcgtg-3 0 ; GFP-R, 5 0 -gctgaacttgtggccgtttac-3 0 ; b-Actin-F, 5 0 -ttcacctgccctgagtgtttc-3 0 ; b-Actin-R, 3 0 -gggagagcatagccctcgta-5 0 ; CaMKIIa-F, 5 0 -agca caagcagaaactggga-3 0 ; CaMKIIa-R, 5 0 -tgaatcgggtgcaggtgatg-3 0 ; ERK2-F, 5 0 -tgtgttgtcctccttcctcg-3 0 ; ERK2-R, 5 0 -tcgccctgtaaaag gacttc À3 0 . The PCR product was purified by QiaQuick gel extraction kit (QIAGEN) and then proceeded to DNA sequencing using the following primers: b-Actin-S, 5 0 -gaacagccttcttagcaccg-3 0 ; CaMKIIa-S, 5 0 -agccctagttcccagcctaa-3 0 ; ERK2-S, 5 0 -caggagt gaaggccaagaag-3 0 .
AAV vector production
All custom AAV vectors were produced by the Penn Vector Core at the University of Pennsylvania or Vigene Biosciences. The titers of AAV-HDR pseudotyped with serotype 1 were 1.8 3 10 13 (HA-b-Actin), 1.1 3 10 13 (HA-mouse-CaMKIIa), 1.3 3 10 13 (HArat-CaMKIIa), 1.6 3 10 13 (HA-ERK2), 1.1 3 10 13 (mEGFP-b-Actin), 2.1 3 10 13 (mEGFP-CaMKIIa), and 3.5 3 10 12 (AAV-EFS-Cas9) GC/mL. The titer of AAV-HDR pseudotyped with serotype 9 was 6.5 3 10 13 (HA-CaMKIIa) GC/mL. All premade AAV vectors were purchased from the Penn Vector Core at the University of Pennsylvania. The viral vectors used, with their abbreviated names as used in the text, are as follows: AAV1.CB7.CI.eGFP.WPRE.rBG (AAV-EGFP), AAV1.CB7.CI.mCherry.WPRE.rBG (AAV-mCherry), AAV1.CAG.Flex.tdTomato.WPRE.bGH (AAV-FLEX-tdTomato), and AAV9.CamKII0.4.Cre.SV40 (AAV-Cre).
Viral transduction into cultures in vitro
For viral transduction into hippocampal organotypic slice cultures, AAV-HDR and/or AAV-EFS-Cas9 and/or AAV-EGFP were directly added onto cultures at DIV5-8. The applied amount of AAV-HDR and AAV-EFS were as follows (per slice): AAV-HDR for HA-CaMKIIa,
QUANTIFICATION AND STATISTICAL ANALYSIS
Data collection and analyses were not performed blind. Data from all animals used in the experiments were included in the statistical analysis and data plots. Sample sizes were not predetermined with statistical methods. Quantitative data are presented as mean ± SEM. The details of sample number (n) including exact values are indicated in the main text and/or figure legends. The Student's t test was used when two independent samples were compared. Statistical analyses were conducted using Prism 7 software (GraphPad Software). Differences between datasets were judged to be significant at p < 0.05.
